DYRK1A in Down syndrome: An oncogene or tumor suppressor?

Journal of Clinical Investigation

Volumn 122, Issue 3, 2012, Pages 807-810

  Birger, Yehudit ^a   Izraeli, Shai ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR NFAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; CHROMOSOME 21; DISEASE ASSOCIATION; DISEASE COURSE; DOWN SYNDROME; DYRK1A GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; NOTE; ONCOGENE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 21; DOWN SYNDROME; HUMANS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES;

EID: 84857809799     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI62372     Document Type: Note

References (23)

1. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol. 2001;2(7):429-436. (Pubitemid 33585947)
2. Malinge S, et al. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest. 2012;122(3):948-962.
3. Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood. 2009;113(12):2619-2628.
4. Chou ST, et al. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood. 2008;112(12):4503-4506.
5. Tunstall-Pedoe O, et al. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood. 2008;112(12):4507-4511.
6. Izraeli S. Trisomy 21 tilts the balance. Blood. 2008;112(12):4361-4362.
7. Hertzberg L, et al. Prediction of chromosomal aneuploidy from gene expression data. Genes Chromosomes Cancer. 2007;46(1):75-86. (Pubitemid 44772874)
8. De Vita S, et al. Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome. Oncogene. 2010;29(46):6102-6114.
9. Salek-Ardakani S, et al. ERG is a megakaryocytic oncogene. Cancer Res. 2009;69(11):4665-4673.
10. Stankiewicz MJ, Crispino JD. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood. 2009;113(14):3337-3347.
11. Ng AP, et al. Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome. Blood. 2010;115(19):3966-3969.
12. Klusmann JH, et al. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev. 2010;24(5):478-490.
13. Park J, Song WJ, Chung KC. Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell Mol Life Sci. 2009;66(20):3235-3240.
14. Arron JR, et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature. 2006;441(7093):595-600. (Pubitemid 43927286)
15. Muller MR, Rao A. NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol. 2010;10(9):645-656.
16. Li X, et al. Calcineurin-NFAT signaling critically regulates early lineage specification in mouse embryonic stem cells and embryos. Cell Stem Cell. 2011;8(1):46-58.
17. Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011;164(1):9-16.
18. Lima FA, et al. Decreased AIRE expression and global thymic hypofunction in Down syndrome. J Immunol. 2011;187(6):3422-3430.
19. Baek KH, et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature. 2009;459(7250):1126-1130.
20. Giraudier S, et al. Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood. 2002;100(8):2932-2940.
21. Ge Y, et al. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia. 2008;22(3):521-529. (Pubitemid 351386721)
22. Ozery-Flato M, Linhart C, Trakhtenbrot L, Izraeli S, Shamir R. Large-scale analysis of chromosomal aberrations in cancer karyotypes reveals two distinct paths to aneuploidy. Genome Biol. 2011;12(6):R61.
23. Chou ST, VanDorn D, Yao Y, French DL, Weiss MJ. 2011. Patient-derived induced pluripotent stem cells reveal distinct hematopoietic defects conferred by Trisomy 21 and truncated GATA-1. Abstract #911 presented at: 53rd Annual American Society of Hematology Meeting. December 13, 2011. San Diego, California, USA.